ERBB2 and breast cancer: This indicates that the development of small molecule targeted therapy against HER3 for use in HER2+ breast cancer needs to be directed away from stabilising the HER3 ATP binding pocket occupied conformer and rather towards stabilising the apo, inactive conformer.